Meanwhile, sales of the products introduced to replace Advair/Seretide missed consensus estimates, with Breo (fluticasone furoate and vilanterol) bringing in £11 million and Anoro (umeclidinium ...
It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to revive the fortunes of its respiratory diseases franchise. The company had been propped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback